DreamCIS, Inc.
Financials
Valuation Metrics
DreamCIS, Inc.'s Market Cap is ₩775B. At end of 2025 it was ₩1570B. Ranked #1450 of 2,421 in KR market (top 60%), #834 of 1,640 on KOSDAQ (top 51%), #155 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 67%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 77.49B KRW | KR#1,450/2,421 Sec#155/231 |
| Revenue | 73.28B KRW | KR#1,597/2,421 Sec#103/231 |
| Net Income | 640.0M KRW | KR#1,512/2,421 Sec#104/231 |
| Total Assets | 159.49B KRW | KR#1,468/2,421 Sec#112/231 |
| Net Assets | 84.19B KRW | KR#1,548/2,421 Sec#123/231 |
| Employees | 358 | KR#677/2,421 Sec#59/231 |
| Value | ||
| P/E | 121.07x | KR#1,499/2,421 Sec#102/231 |
| P/B | 0.92x | KR#1,390/2,421 Sec#86/231 |
| P/S | 1.06x | KR#1,419/2,421 Sec#85/231 |
| EV/EBITDA | 13.59x | KR#800/2,421 Sec#47/231 |
| FCF Yield | 17.47% | KR#370/2,421 Sec#8/231 |
| Profitability | ||
| ROE | 0.76% | KR#1,499/2,421 Sec#105/231 |
| ROA | 0.40% | KR#1,497/2,421 Sec#105/231 |
| Op. Margin | 7.10% | KR#717/2,421 Sec#56/231 |
| Revenue Growth | 14.96% | KR#690/2,421 Sec#65/231 |
| Earnings Growth | -83.20% | KR#1,124/2,421 Sec#74/231 |
| Financial Health | ||
| Debt Ratio | 89.45% | KR#1,455/2,421 Sec#170/231 |
| Total Debt | 14.98B KRW | KR#1,498/2,421 Sec#128/231 |
| FCF | 13.54B KRW | KR#624/2,421 Sec#35/231 |
| Cash | 21.75B KRW | KR#1,201/2,421 Sec#84/231 |
| Current Ratio | 1.04x | KR#1,681/2,421 Sec#168/231 |
| Net Debt/EBITDA | -1.30x | KR#318/2,421 Sec#16/231 |
| Performance | ||
| 1Y Return | -16.89% | KR#1,171/2,421 Sec#79/231 |
| 1M Return | -4.69% | KR#1,768/2,421 Sec#140/231 |
| From 52W High | -63.54% | KR#1,990/2,421 Sec#160/231 |
| 1Y MDD | -68.14% | KR#1,907/2,421 Sec#162/231 |
| Trading | ||
| Volume | 50,604 shares | KR#1,122/2,421 Sec#111/231 |
| Trading Value | 160.1M KRW | KR#1,355/2,421 Sec#138/231 |
| Foreign Own. | 50.12% | KR#35/2,421 Sec#2/231 |
| Per Share | ||
| EPS | 26 KRW | KR#1,535/2,421 Sec#106/231 |
| BPS | 3,422 KRW | KR#1,768/2,421 Sec#131/231 |
Company Info
Dream CIS, a Clinical Research Organization (CRO) established in 2000, saw China's top CRO, Tigermed, acquire a stake in 2015. The company provides full-range services including clinical trial design, consulting, and monitoring, as well as comprehensive specialized services such as drug clinical trials, post-market surveillance, and statistical analysis. Leveraging Tigermed's global network, Dream CIS establishes a foundation for multinational clinical trial orders and secures competitiveness through the integration of standard operating procedures. Dream CIS was established in 2000 and is headquartered in Jongno-gu, Seoul.